Literature DB >> 22451756

Cotrimoxazole-resistant Escherichia coli bacteremia in neutropenic patients at a regional oncology hospital.

D B Gregson1, A G Matlow, A E Simor, P G Tuffnell, D E Low, R Feld, J E Brunton.   

Abstract

In a regional oncology hospital using cotrimoxazole (trimethoprim-sulphamethoxazole) prophylaxis during chemotherapy-induced neutropenia, a single strain of Escherichia coli (indole negative) caused 15 of 27 episodes of Gram-negative rod bacteremia in 1987, and four of 32 such episodes in 1988. This biotype had not been recovered in 1986. Investigations during this 'outbreak' of bacteremias revealed enteric colonization with this strain of E coli in 37% of patients on leukemia or bone marrow transplant wards and in several staff members in July 1987. In 1988, 11 of 32 Gram-negative rod bacteremias were secondary to other strains of indole positive E coli of several different biotypes and plasmid profiles. Indole negative strains all exhibited low level trimethoprim resistance, whereas indole positive strains which subsequently appeared exhibited high level trimethoprim resistance. Failure of cotrimoxazole prophylaxis was initially due to the clonal dissemination of a single strain of E coli within the institution, with the subsequent appearance of multiple E coli strains with probable differing genetic bases for their resistance.

Entities:  

Keywords:  Cotrimoxazole; Escherichia coli; Infections; Neutropenia; Septicemia; Trimethoprim resistance; Trimethoprim-sulphamethoxazole

Year:  1992        PMID: 22451756      PMCID: PMC3307421          DOI: 10.1155/1992/140845

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  11 in total

Review 1.  Antimicrobial prophylaxis for infection in neutropenic patients.

Authors:  G P Bodey
Journal:  Curr Clin Top Infect Dis       Date:  1988

2.  Failure of trimethoprim/sulfamethoxazole as prophylactic therapy of gram-negative sepsis in pediatric patients with cancer.

Authors:  C Esquembre; J Ferris; A Verdeguer; V Castel
Journal:  Pediatrics       Date:  1986-10       Impact factor: 7.124

3.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

Review 4.  Trimethoprim resistance.

Authors:  P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

5.  Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients. Reduction of infections and effect on bacterial and fungal flora.

Authors:  C A Kauffman; M K Liepman; A G Bergman; J Mioduszewski
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

6.  Failure of oral trimethoprim-sulfamethoxazole prophylaxis in acute leukemia: isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia.

Authors:  J M Wilson; D G Guiney
Journal:  N Engl J Med       Date:  1982-01-07       Impact factor: 91.245

7.  Incidence of trimethoprim-sulfamethoxazole-resistant enterobacteriaceae among transplant recipients.

Authors:  C L Wells; R P Podzorski; P K Peterson; N K Ramsay; R L Simmons; F S Rhame
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

8.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

9.  Selective antimicrobial modulation of the intestinal flora of patients with acute nonlymphocytic leukemia: a double-blind, placebo-controlled study.

Authors:  H F Guiot; P J van den Broek; J W van der Meer; R van Furth
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

10.  Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies.

Authors:  R J Gualtieri; G R Donowitz; D L Kaiser; C E Hess; M A Sande
Journal:  Am J Med       Date:  1983-06       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.